GlassScriptPhysician profile
Latoya S Clark
NPI 1346566700
$3,654.21
in general payments reported to CMS, 2019-2025
46 companies · $524 in 2025
The $524 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $400 · 2021: $346 · 2022: $537 · 2023: $313 · 2024: $456 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $538.82 | 2019-2024 | Liletta |
| Becton, Dickinson and Company | $313.58 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $304.73 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $265.69 | 2019-2025 | Veozah |
| Intuitive Surgical, INC. | $155.32 | 2019-2022 | |
| Pfizer INC. | $140.00 | 2019-2023 | |
| Therapeuticsmd, INC. | $127.47 | 2019-2021 | |
| Novo Nordisk INC | $122.28 | 2019-2025 | Ozempic, Rybelsus |
| Hologic Sales and Service, LLC | $105.82 | 2019-2025 | Aptima |
| Medical Device Business Services, INC. | $102.99 | 2021 | |
| Lilly USA, LLC | $96.39 | 2024-2025 | Mounjaro, Zepbound |
| Scynexis, INC. | $95.09 | 2022 | |
| Roche Diagnostics Corporation | $82.73 | 2019-2020 | |
| Leo Pharma INC. | $78.67 | 2022 | |
| Viiv Healthcare Company | $74.34 | 2024 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latoya Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.